Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
163,2 USD | -0,35% | +2,61% | +5,69% |
30/04 | Alvotech gaat Humira Biosimilar Adalimumab-ryvk maken voor Quallent | MT |
29/04 | ABBVIE INC. : BMO Capital bevestigt koopadvies | ZM |
Omzet 2024 * | 54,91 mld. 50,92 mld. | Omzet 2025 * | 57,95 mld. 53,74 mld. | Marktkapitalisatie | 289 mld. 268 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 8,22 mld. 7,62 mld. | Nettowinst (verlies) 2025 * | 10,98 mld. 10,18 mld. | EV/omzet 2024 * | 6,24 x |
Nettoschuld 2024 * | 53,44 mld. 49,56 mld. | Nettoschuld 2025 * | 47,17 mld. 43,74 mld. | EV/omzet 2025 * | 5,8 x |
K/w-verhouding 2024 * |
31,3
x | K/w-verhouding 2025 * |
24,2
x | Werknemers | 50.000 |
Dividendrendement 2024 * |
3,77% | Dividendrendement 2025 * |
3,96% | Vrij verhandelbaar | 96,75% |
Recentste transcriptie over AbbVie Inc.
1 dag | +0,26% | ||
1 week | +2,61% | ||
Lopende maand | +0,71% | ||
1 maand | -3,65% | ||
3 maanden | -4,36% | ||
6 maanden | +15,82% | ||
Lopend jaar | +5,69% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 01-01-13 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 01-01-13 |
Robert Michael
PSD | President | 53 | 01-01-12 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 01-01-13 |
Edward Rapp
BRD | Director/Board Member | 66 | 01-01-13 |
Director/Board Member | 70 | 01-01-13 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
7.12% | 6 M€ | +4,80% | - | |
6.85% | 18 M€ | +3,01% | - | |
6.26% | 13 M€ | -.--% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
06-05-24 | 164,4 | +0,38% | 2 174 |
03-05-24 | 163,8 | +1,85% | 5 850 102 |
02-05-24 | 160,8 | -0,56% | 5 904 251 |
01-05-24 | 161,7 | -0,57% | 5 178 876 |
30-04-24 | 162,6 | +0,69% | 5 484 841 |
uitgestelde koers Nyse, 03 mei 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,69% | 289 mld. | |
+26,08% | 662 mld. | |
+20,58% | 546 mld. | |
-4,77% | 359 mld. | |
+16,97% | 323 mld. | |
+13,68% | 234 mld. | |
+4,12% | 198 mld. | |
-10,51% | 194 mld. | |
+8,08% | 167 mld. | |
-3,40% | 157 mld. |